---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-273406"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:40:15.955110+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Verrica appoints David Zawitz as COO effective Dec 9; grants 950,000 option shares

## Summary
- David Zawitz appointed Chief Operating Officer and principal operating officer, effective Dec 9, 2024.
- Base salary of $250,000/year; target annual bonus of 40% of base salary.
- Option grant for 950,000 shares at closing price on grant date, vesting over 4 years with accelerated vesting on change-in-control termination.
- 2024 Inducement Plan shares increased from 2,000,000 to 4,500,000 to accommodate the grant.
- Zawitz to continue consulting for PBM Capital with Board approval for increased time.

## SEC filing metadata
- accession: 0001193125-24-273406
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524273406/0001193125-24-273406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524273406/d878105d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-273406
- JSON: https://secwatch.observer/filing/0001193125-24-273406.json
- Plain text: https://secwatch.observer/filing/0001193125-24-273406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.